Abstracts tagged "Infection"

Abstract Number: 0632 • ACR Convergence 2020
Systems Approach to Understanding Reasons for Influenza Vaccine Hesitancy in Rheumatic Diseases
Valeria Valerio¹, Mariana Useche¹, Erin Field², Mianbo Wang³, Elizabeth M. Hazel⁴, Brian Ward⁵ and Ines Colmegna¹, ¹The Research Institute of the McGill University Health Centre, Montreal, Canada, ²The Research Institute of the MUHC, Montreal, Canada, ³Lady Davis institute for Medical Research, Montreal, QC, Canada, ⁴McGill University Health Centre, Montreal, Canada, ⁵The Research Institute of the McGill University Health Centre, Monreal, QC, Canada
Background/Purpose: A vaccination coverage goal of 80% with the seasonal influenza vaccine was established to protect people at high-risk for influenza-related complications or hospitalizations (e.g.…
Abstract Number: 1478 • ACR Convergence 2020
A Multidisciplinary Registry of Patients with Autoinmune and Immune-Mediated Diseases with Symptomatic COVID-19 Infection from a Single Center
Juan C Sarmiento-Monroy¹, Gerard Espinosa², Fernanda Meira¹, Berta Caballol³, Maria C Londoño³, Sara Llufriu³, Aina Moll¹, Luis Fernando Quintana Porras¹, Felipe Julio Ramirez Garcia⁴, José Inciarte-Mundo¹, Elisabeth Solana¹, Yolanda Blanco¹, Eugenia Martinez¹, Victor Llorens¹, Sergio Prieto-González⁵, Georgina Espigol¹, Jose C Milisenda¹, Maria C. Cid⁵, Priscila Giavedoni¹, Jose M Mascaró¹, Isabel Blanco¹, Joan Albert Barbera¹, Oriol Sibila¹, Jordi Gratacos-Gines¹, Alfredo Adan², Alvaro Agustí¹, Raimon Sanmartí⁶, Julián Panés¹, Ricard Cervera¹, Jordi Vila¹, Alex Soriano¹, Jose Gómez-Puerta⁶ and On behalf INMUNOCOVID CLINIC⁷, ¹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²Hospital Clinic, Barcelona, Catalonia, Spain, ³Hospital Clinic de Barcelona, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁵Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Hospital Clinic de Barcelona, Barcelona
Background/Purpose: National health authorities reported a prevalence of SARS-CoV-2 infection around 7% of the general population in Barcelona county (1). A recent report focused on…
Abstract Number: 0227 • ACR Convergence 2020
Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
Lucía Vega-Álvarez¹, Itziar Calvo-Zorrilla¹, Oihane Ibarguengoitia-Barrena¹, Juan M. Blanco-Madrigal¹, David Montero-Seisdedos², Carmen L. Garcia-Gomez¹, Maria Esther Ruiz-Lucea¹, Ana R. Inchaurbe-Pellejero¹, Ignacio Torre-Salaberri¹, Clara E. Perez-Velasquez¹, Olaia Fernandez-Berrizbeitia¹, Eduardo Cuende-Quintana³, Iñigo R. Gorostiza-Hormaetxe⁴, María Luz García-Vivar¹ and Eva Galindez-Agirregoikoa¹, ¹Basurto University Hospital, BILBAO, Spain, ²Basurto University Hospital, Bilbao, Pais Vasco, Spain, ³Basurto University Hospital, Madrid, Spain, ⁴Basurto University Hospital, Bilbao
Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
Abstract Number: 0633 • ACR Convergence 2020
Vitamin D Serum Status in a Cohort of COVID-19 Patients
Alberto Sulli¹, Emanuele Gotelli¹, Sabrina Paolino¹, Andrea Casabella¹, Carmen Pizzorni¹, Elisa Alessandri¹, Vanessa Smith² and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic, Genoa, Italy, ²Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium
Background/Purpose: Vitamin D serum levels have been inversely associated with risk of pulmonary infections and autoimmune inflammatory disease activity and severity [1,2]. A possible role…
Abstract Number: 1568 • ACR Convergence 2020
Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study
Nilasha Ghosh¹, Aidan Tirpack², Caroline Benson³, Gregory Vitone³, Karmela Kim Chan² and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…
Abstract Number: 008 • 2020 Pediatric Rheumatology Symposium
Incidence and Risk Factors of Hypogammaglobulinemia and Infectious Complications Associated with Rituximab Use in Pediatric Rheumatic Diseases
Mei-Sing Ong¹, Deborah Rothman ² and Marc Natter ³, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Massachusetts General Hospital, Springfield, ³Boston Children's Hospital, Boston
Background/Purpose: B-cell depletion therapy has increasingly been used for the treatment of childhood-onset rheumatic diseases. Previous studies investigating whether rituximab results in increased infections have…
Abstract Number: 069 • 2020 Pediatric Rheumatology Symposium
Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
Liora Harel ¹, Gil Amarilyo ² and mohammad hammad saied³, ¹Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ²Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel, ³Schneider Medical Center, Kaboul village 24963, Israel
Background/Purpose: Rheumatic Fever (RF) occurs after a pharyngeal infection caused by group A-B-hemolytic streptococci.Its principal clinical significance is causing carditis at the acute phase of…
Abstract Number: 138 • 2020 Pediatric Rheumatology Symposium
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Simone Melega ¹, Paul Brogan², Gavin Cleary ³, Aimee Hersh ⁴, Ozgur Kasapcopur ⁵, Satyapal Rangaraj ⁶, Rae Yeung ⁷, Andrew Zeft ⁸, Jennifer Cooper ⁹, Pooneh Pordeli ¹⁰, Petra Kirchner ¹¹ and Patricia Lehane ¹², ¹F. Hoffmann-La Roche, Ltd., Basel, Switzerland, ²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ³Alder Hey Children's Hospital, Liverpool, United Kingdom, ⁴University of Utah Primary Children's Hospital, Salt Lake City, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Cerrahpasa, Turkey, ⁶Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ⁷The Hospital for Sick Children, Toronto, Canada, ⁸The Cleveland Clinic - Center for Pediatric Rheumatology & Immunology, Cleveland, Ohio, ⁹University of Colorado, Children's Hospital Colorado, Denver, ¹⁰F. Hoffmann-La Roche, Ltd., Mississauga, Canada, ¹¹F. Hoffmann-La Roche Ltd., Birsfelden, Switzerland, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Low immunoglobulin (Ig) levels can occur after rituximab treatment, but the clinical significance is not completely understood. Not all patients (pts) who develop low…
Abstract Number: 2873 • 2019 ACR/ARP Annual Meeting
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy – Nationwide Results from Iceland
Aron H Bjornsson¹, Olafur Palsson ², Mar Kristjansson ³, Petur S Gunnarsson ⁴, Gerdur Grondal ⁵, Bjorn Gudbjornsson ⁶ and Thorvardur J Love ⁷, ¹Department of Medicine, Landspitali, Reykjavík, Iceland, ²Department of Clinical Sciences Lund, Lund University and Skåne University Hospital, Lund, Sweden, ³Department of Infectious Diseases, Landspitali, Reykjavík, Iceland, ⁴Faculty of Pharmaceutical Sciences, University of Iceland and Hospital Pharmacy, Landspitali, Reykjavík, Iceland, ⁵Department of Rheumatology, Landspitali and Centre for Rheumatology Research, Landspitali, Reykjavík, Iceland, ⁶Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁷Faculty of Medicine, University of Iceland and Department of Science, Landspitali, Reykjavík, Iceland
Background/Purpose: Severe infections, frequently resulting in hospitalization, are a well-known adverse effects of tumor necrosis factor inhibitors (TNFi). However, studies regarding outpatient treated infections are…
Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Michael George¹, Joshua Baker ², Kevin Winthrop ³, Qufei Wu ², Lang Chen ⁴, Fenglong Xie ⁵, Huifeng Yun ⁴ and Jeffrey Curtis ⁴, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Oregon Health and Science University, Portland, OR, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…
Abstract Number: 951 • 2019 ACR/ARP Annual Meeting
Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences
Candace Feldman¹, Chang Xu ¹ and Karen Costenbader ¹, ¹Brigham and Women's Hospital, Boston, MA
Background/Purpose: Nearly 25% of patients with SLE are hospitalized each year often for outcomes that may have been avoided if patients had received sustained, high…
Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Huan Huang ³, Lawrence Chang ², Xin Wang ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth Meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Marina Magrey¹, Victoria Navarro-Compán ², Sandra Garces ³, Xenofon Baraliakos ⁴, David Sandoval ³, Jeffrey Lisse ³, Silvia Santisteban ³, David Adams ³, Fangyi Zhao ³ and Robert Inman ⁵, ¹Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Marianne Kerski¹, Peter Boersma ², Eric Miller ³, Ashley Brenner ⁴, Genevieve Melton ⁵ and Anna Shmagel ⁶, ¹University of Minnesota Medical School, Minneapolis, MN, ²University of Minnesota School of Public Health, Minneapolis, ³University of Minnesota, Woodbury, MN, ⁴University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, ⁵University of Minnesota Department of Surgery, Minneapolis, MN, ⁶University of Minnesota, Minneapolis, MN
Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
Abstract Number: 2095 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients
Kieran Murray¹, Candice Low ¹, Francis Young ¹, Anna O'Rourke ¹, Ian Callanan ², Eoin Feeney ¹ and Douglas Veale ³, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin, Dublin, Ireland, ³EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].